PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Autoimmun. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
PMCID: PMC2783278
NIHMSID: NIHMS145657

Alternatively activated macrophages in infection and autoimmunity

Abstract

Macrophages are innate immune cells that play an important role in activation of the immune response and wound healing. Pathogens that require T helper-type 2 (Th2) responses for effective clearance, such as parasitic worms, are strong inducers of alternatively activated or M2 macrophages. However, infections such as bacteria and viruses that require Th1-type responses may induce M2 as a strategy to evade the immune system. M2 are particularly efficient at scavenging self tissues following injury through receptors like the mannose receptor and scavenger receptor-A. Thus, M2 may increase autoimmune disease by presenting self tissue to T cells. M2 may also exacerbate immune complex (IC)-mediated pathology and fibrosis, a hallmark of autoimmune disease in women, due to the release of profibrotic factors such as interleukin (IL)-1β, transforming growth factor-β, fibronectin and matrix metalloproteinases. We have found that M2 comprise anywhere from 30% to 70% of the infiltrate during acute viral or experimental autoimmune myocarditis, and shifts in M2 populations correlate with increased IC-deposition, fibrosis and chronic autoimmune pathology. Thus, women may be at an increased risk of M2-mediated autoimmunity due to estrogen’s ability to increase Th2 responses.

Keywords: Autoimmunity, Complement, Cytokines, Infection, Macrophage

Introduction

A number of excellent reviews have been written in the past few years describing macrophage activation and polarization [see 14]. The aim of this review is to highlight the role of infection and tissue damage in directing macrophage phenotype and the impact polarized macrophage populations have on the initiation and propagation of autoimmune diseases. The influence of sex hormones on macrophage polarization and function will also be examined. Most of the discussion of alternatively activated macrophages in this review will focus on research conducted in animal models.

1. Classification of macrophages

Macrophages are innate immune cells that play a key role in normal tissue homeostasis, presentation of foreign and self antigens following infection or injury, pathogen clearance, resolution of inflammation and wound healing [1,2,57]. Following antigen stimulation immature monocytes emigrate from blood vessels into peripheral tissues where they differentiate into mature macrophages and dendritic cells (DCs) comprising as much as 15% of total cells [1,7]. Macrophages are considered classically activated (M1) when stimulated by interferon (IFN)-γ or lipopolysaccharide (LPS) to release nitric oxide (NO), important for killing intracellular pathogens, and alternatively activated (M2) when stimulated by interleukin (IL)-4 or IL-13 (M2a) to produce IL-10, transforming growth factor (TGF)-β and arginase-1 (Arg1), important for killing extracellular parasites [3]. M2 can be further subdivided to those induced by immune complexes (ICs) and LPS or IL-1β (M2b) or those induced by IL-10, TGF-β or glucocorticoids (GC) (M2c) [2]. Thus, LPS and IL-1β, acting through Toll-like receptor (TLR)4 and IL-1R signaling, respectively, are associated with both M1 and M2 responses. Other suppressive or anti-inflammatory macrophages include tumor-associated macrophages (TAM) and “immature” monocyte-like (GR1/Ly6C+) or “mature” neutrophil-like (GR1/Ly6G+) myeloid-derived suppressor cells (MDSCs). Because IL-4 and IL-13 are not required for the differentiation of TAM or MDSCs, these macrophage populations are usually not referred to as alternatively activated [3]. Keep in mind that NO released from IFN-γR+ M1 down-regulates T cell responses and so M1 can also be considered “suppressive” [8]. Importantly, macrophages are not “permanently differentiated” in the way we consider T helper-type 1 (Th1) or Th2 cells to be, but are “plastic”-able to move from macrophage to DC and back again and from M1 to M2 depending on the local environment [7].

1.1 Classically activated macrophages

Classically activated or M1 macrophages develop in culture in response to stimulation by IFN-γ and LPS. IFN-γ is produced by many cell types including CD8+ cytotoxic T lymphocytes, natural killer (NK) and Th1 cells [2]. M1 are characterized by expression of MHC class II and CD86 and their ability to secrete proinflammatory cytokines such as tumor necrosis factor (TNF)-α, IL-1β, IL-12, IL-18 and the chemokines CCL15, CCL20, CXCL8-11 and CXCL13 [2,3]. M1 efficiently kill intracellular pathogens by endocytosis of bacteria and viruses, production of NO via IFN-γ-inducible NO synthase (iNOS), synthesis of reactive oxygen intermediates (ROI), and by restriction of iron and other nutrients required for bacterial growth and viral replication [2].

1.2 Alternatively activated macrophages

Alternatively activated or M2 macrophages were originally named “alternative” because they could be induced by IL-4 rather than IFN-γ. Monocytes differentiate into M2 in culture in response to IL-4, IL-13, IL-10, TGF-β, GC, ICs, LPS and/or IL-1β [2]. In general, M2 are distinguished from other macrophage populations by several markers including the IL-4R, mannose receptor (MR/CD206), Arg1, Fizz1 (found in inflammatory zone), PPARγ (peroxisome proliferator-activated receptor) and Ym1/2 (eosinophilic protein from chitinase family) [3]. IL-4 and IL-13 are produced by mast cells (MCs), Th2 cells and eosinophils, stimulate Arg1 production via STAT6, and upregulate the MR, scavenger receptor (SR)-A and C-type lectins (CLECs) such as MGL1/2. IL-10 is produced by MCs, T and B cells, and macrophages and induces differentiation of monocytes to macrophages while blocking their differentiation to DCs [9].

M2 are typically associated with Th2 responses and tissue repair where they are thought to increase fibrosis by expressing profibrotic factors such as fibronectin, matrix metalloproteinases (MMPs), IL-1β and TGF-β. However, a definitive role for M2 in mediating fibrosis has not yet been established in vivo [3]. IL-10 and TGF-β released from macrophages have been found to inhibit LPS/TLR4-mediated production of TNF-α and IL-1β [10] and downregulate Th1 responses by increasing CD4+Foxp3+ regulatory T cells (Treg) [11]. M2 are characterized by producing Arg1 rather than iNOS/NO, which makes them highly effective at eliminating parasitic helminth infections but significantly compromises their ability to kill intracellular pathogens [12,13]. However, this distinction between iNOS in M1 vs. arginase in M2 is absent in human macrophages [11]. The MR is upregulated on M2 by IL-4, IL-13 or IL-10 and down-regulated by proinflammatory cytokines [14]. MR signaling inhibits Th1 responses by interfering with TLR/IL-1R-mediated signaling by upregulating IL-1R type II (a decoy receptor) and by secretion of the IL-1R antagonist (IL-1Ra) and IL-10 [3,15]. Importantly, expression on M2 of scavenger receptors and C-type lectins like the MR and DC-SIGN serve not only as pattern recognition receptors for pathogen binding and uptake during infection, but also bind self tissues such as apoptotic cells and oxidized LDL as a part of natural homeostasis and tissue repair [1,16,17]. Thus, M2 are increased in response to many infections, particularly those associated with Th2 responses, and are important in mediating wound healing following tissue damage.

1.3 Myeloid-derived suppressor cells

MDSCs are considered to be an immature population of myeloid cells associated with infections or tumors that are cable of suppressing proinflammatory responses [4,1820]. Mouse MDSCs have been found to express CD11b, GR1 (Ly6C or Ly6G), F4/80, CD80, STAT3, IL-4Rα, Arg1, iNOS, ROS, IL-10, and TGF-β. MDSCs are separated into monocyte-like suppressor cells that express NO (ROS undetectable) and neutrophil-like suppressor cells that express ROS (NO undetectable) [4,11]. Like M2, IL-4 and IL-13 promote MDSC development along with IL-10, TGF-β, IL-1β and LPS/TLR4. However, MDSCs differ from M2 in that they are dependent on IFN-γ to produce NO, ROS and Treg. Thus, MDSCs display an array of M1 and M2 characteristics further emphasizing the malleable nature of macrophages.

CD11b+GR1+ MDSCs are present in most cancers in humans and mice and bear many similarities to M2 and TAM [1,4,11]. MDSCs induced by infection or tumors inhibit innate and adaptive immune responses and drive monocytes to a macrophage rather than a DC phenotype [21]. During damage induced by myocardial infarction, Ly-6Chi monocytes were found to digest damaged tissue early after acute injury, while Ly-6Clo monocytes promoted tissue repair by stimulating myofibroblast formation, angiogenesis and deposition of collagen [6]. Thus, MDSCs also appear to be important for wound healing in response to tissue damage. MDSCs are not always observed as immature Ly6C+ populations, but can also express markers of mature macrophages such as Ly6G and MHC class I or II [18,22,23]. Thus, a proportion of GR1+Ly6G+ cells that are identified in studies as neutrophils may in fact be neutrophil-like MDSCs [24]. MDSCs have been shown to directly suppress NK, CD4+ and CD8+ T cell function via Arg1 and are associated with increased Treg and Th2 responses. For example, influenza virus infection of mice was found to increase MDSCs that inhibited antiviral NK cell responses resulting in increased viral replication [19]. Thus, MDSCs are thought to be induced by infections that are typically cleared by Th1 or Th17 responses as a strategy to evade elimination by the immune system.

1.4 Tumor associated macrophages

Similarly, tumors are able to escape immune system control by secreting anti-inflammatory cytokines such as IL-10, TGF-β and prostaglandins (i.e. PGE2) that direct macrophages to a suppressive phenotype called TAM [2,11,21,22]. TAM directly inhibit CD4+ and CD8+ T cell-mediated tumor killing in humans and mice via cell-to-cell contact and release of TGF-β and NO [22]. Like MDSCs, TAM express CD11b, GR1, F4/80, NO, Arg1, STAT1, STAT3 and TGF-β [11,25,26]. Only a small number of TAM are needed to shut down tumor-specific T cell killing, which does not induce global suppression of the immune response. Thus, a patient’s immune system may appear to function normally while the tumor grows. TAM express many of the same markers as MDSCs and M2, such as the MR, SR-A and TGF-β, and the term MDSC is often used interchangeably with TAM [4]. Like MDSCs, TAM also express typical M1 markers such as the proinflammatory cytokines TNF-α, IL-1β and IL-6. However, TAM are generally considered to be poor producers of NO and ROI compared to M1 or MDSCs [2]. Similar to M2 and MDSCs, TAM are able to scavenge cellular debris following tissue damage and are important in angiogenesis, lymphogenesis, tissue remodeling and repair- functions that promote tumor progression and metastasis [27,28]. Thus, TAM, MDSCs and M2 share many features in common such as inhibiting proinflammatory responses, being activated by self-antigens following tissue damage, and mediating extracellular matrix remodeling and wound repair. In the next section, we will describe how suppressive macrophage populations induced by infection and tissue damage (or adjuvant and self-peptides in animal models) play a key role in the development of autoimmune disease.

2. Infection, M2 and autoimmune disease

2.1 Infection and injury in AD

For some time infections have been postulated to play a role in the initiation and/or promotion of autoimmune diseases (ADs). The role of infection has been difficult to substantiate for a number of reasons. Many of the infections suspected to cause ADs are widespread in the population, such as coxsackievirus or cytomegalovirus, and often an active infection can no longer be detected by the time the signs and symptoms of AD appear [29]. Several theories have been proposed to explain mechanistically how infections could induce ADs including persistent infection, molecular mimicry, the bystander effect and the adjuvant effect [3035]. It is clear that physical injury must occur in target tissues in order to release self antigens, and so infections may be able to damage tissue as well as providing the adjuvant stimulus needed for the development of AD. A better understanding of the innate immune response has revealed that adjuvants like complete Freund’s adjuvant (CFA) and pertussis toxin increase inflammation not simply by acting as a depot for self antigens or by increasing vascular permeability, respectively, but by activating the innate immune response via pathogen pattern recognition receptors (PRRs) such as TLR2 and TLR4 [3640]. It must be emphasized that self-antigens do not induce AD in animal models unless administered at the same time as adjuvant, indicating that simultaneous activation of PRRs by microbial peptides (provided by inoculation of adjuvant or infection) and self peptides is critical for the development of an autoimmune response. TLR4, in particular, plays a key role in certain ADs such as arthritis and myocarditis, perhaps because of its unique ability to respond to/interact with damaged self peptides like heat shock protein (Hsp)90 and HMGB1 from dying cells as well as various bacterial (i.e. LPS) and viral (i.e. RSV, MMTV, CVB3) peptides [29,30,32,4144].

TLR signaling not only initiates proinflammatory responses, but is key in their regulation. For example, TLR4 signaling is necessary for the development of Treg during acute coxsackievirus B3 (CVB3)-induced myocarditis- an autoimmune model of myocarditis induced by inoculation with infectious virus and heart tissue [42,45]. Increasing evidence indicates that TLR expression on Treg influences their ability to regulate infection and AD [46]. T cell Ig mucin (Tim) receptor-mediated signaling is another important pathway that inhibits proinflammatory responses in AD models like experimental autoimmune encephalomyelitis (EAE) and CVB3-induced myocarditis [47,48]. Increased Tim-3 expression on the surface of Th1 cells binds galectin-9, which is widely expressed on tissues, directing Th1 cells to undergo apoptosis thereby resolving acute inflammation [49]. We found that around 70% of T cells and 30% of macrophages in the heart during acute CVB3-induced myocarditis express Tim-3, allowing rapid elimination of acute inflammation once CVB3 is cleared [42]. We observe that Tim-3+F4/80+ macrophages also express CD11b and GR1, markers for MDSCs [50]. Importantly, TLR4 and Tim-3 receptor signaling regulate each others expression on MCs and macrophages. In TLR4 deficient mice a significantly higher percentage of MCs, macrophages and T cells express Tim-3 resulting in reduced acute inflammation [42]. In contrast, blocking Tim-3 signaling significantly increases the percentage of MCs and macrophages expressing TLR4 resulting in increased inflammation [42,48]. Knowing the importance of the innate immune response in directing adaptive immunity further emphasizes why concurrent administration of self-antigens and adjuvant is critical for the induction of AD in animal models.

2.2 Infection and M2

Microbes that induce a predominant Th1 or Th17 response include Mycobacterium species, Listeria, Leishmania species, Trypanosoma cruzi and Toxoplasma gondii. TLR and IFNs synergistically trigger NO production that enhances iNOS in M1 enabling them to clear intracellular infections [13]. In contrast, nematode and trematode worms like Nippostrongylus, Toxocara, Schistosoma, and Taenia require an IL-4 or IL-13-driven Th2-type immune response to clear infection, and induce strong M2 responses [3,11,12,51]. Not only do Th2-inducing helminthes such as Schistosoma mansoni and Taenia crassiceps upregulate M2 markers like Arg1, MR, Fizz1 and Ym1 in macrophages in response to infection, but they also induce expression of CD11b, GR1 and F4/80- markers associated with MDSCs (Table 1). This suggests that macrophages considered as MDSCs due to the expression of CD11b and GR1 could perhaps be classified as M2, and visa versa. Table 1 highlights that upregulation of CD11b and GR1 is a common feature following infection, from Th2-inducing helminthes to Th1/Th17-inducing bacteria and viruses. Thus, MDSCs and M2 are generated following infections that require Th1 and/or Th17-type immune responses for clearance, such as Mycobacterium tuberculosis (used to supplement CFA in animal models of AD), Helicobacter pylori, Trypanosoma cruzi, influenza A and CVB3 (Table 1). For example, infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG) was found to suppress NO and to induce Arg1 via TLR2 and MyD88 signaling, pathways usually considered to reflect proinflammatory Th1-type responses [13]. Thus, microorganisms that induce Th1 responses can also direct macrophages to a M2 or MDSC phenotype, perhaps in an attempt to better evade the immune response.

Table 1
Induction of MDSCs and M2 following infection

Following infection or injury, there is often a shift from Th1 to Th2-type immunity as the adaptive immune response progresses from acute to chronic. This shift may also be associated with a change in the proportion of M1 to M2/MDSC at sites of inflammation. Several infections where a shift from Th1 to Th2 has been observed include measles virus, HIV, CVB3, S. mansoni, Plasmodium chabaudi (mouse malaria) and T. cruzi infections [13,52,53]. The mechanism allowing the switch from Th1 to Th2 during S. mansoni infection was identified as an immature population of monocyte-like MDSCs that expressed CD11b, GR1 and F4/80 [8]. Importantly, these cells could be detected within 2 hours of infection with S. mansoni during the innate immune response [8]. The CD11b+GR1+ macrophages had a mixed M1/M2 phenotype similar to MDSCs in that they were IFN-γ and NO-dependent yet secreted TGF-β and IL-10 [51]. A shift from a Th1 to Th2 response is also observed in the progression of ADs from acute to chronic phases and in the process of wound healing following tissue damage [52,53]. Thus, a shift from M1 to M2/MDSC may be a common feature following infection or tissue damage that is important for resolution of inflammation and wound healing.

Because of the ability of helminth infections to induce M2/MDSCs, inoculation with helminths or helminth-glycoproteins/glycolipids has been proposed as a potential therapy for Th1-mediated ADs and other inflammatory conditions. S. mansoni infection was found to inhibit a dextran sodium sulfate (DSS) model of colitis in BALB/c mice [54]. CD11b+F4/80+ macrophages that secreted IL-10 and TGF-β were found to be responsible for the suppressive effect. Although M2/MDSCs are able to inhibit acute Th1-mediated inflammation, it is possible that their release of profibrotic agents such as MMPs, IL-1β and TGF-β could exacerbate the chronic fibrotic pathology associated with many ADs. We will explore this possibility in more detail in the next section.

2.3 Complement and M2

Another aspect of the immune response that is critical for the initiation and regulation of inflammation following infection is the complement system. Complement and complement receptors (CRs) play a central role in immune defense by initiating the rapid destruction of invading microorganisms, promoting phagocytosis via scavenger and Fc receptors, activating the innate and adaptive immune response, and clearing ICs [5557]. Complement components activate the innate immune response by responding to bound antibody and PRRs found on pathogens. Activation leads to the formation of complement split products that have potent proinflammatory properties [58,59]. The opsonins C1q, C3b and iC3b interact with CR1, CR3 and CR4 to promote phagocytosis of pathogens. CR1 (CD35) is a receptor for C1q, C3b, C4b and mannose-binding lectin (MBL) - a C-type lectin. CR1 is important for clearing ICs and is a complement regulator with decay-accelerating and membrane cofactor activities in mice [55,59,60]. CR2 (CD21) is the receptor for the cleavage products of C3 including iC3b, C3dg, and C3d. CR2 expression on B cells plays a major role in the induction of antibody responses and has been proposed as the primary mediator of the adjuvant effect of complement, and has been shown to be necessary for disease development in adjuvant-induced models of AD [57,61,62]. While CR1 and CR2 are encoded on separate genes in man, in the mouse they are derived from the same gene, Cr2, so that mice deficient in one receptor are also deficient in the other [63,64]. The β2 integrin CR3 (CD11b/CD18), also called Mac-1, binds C3b and iC3b opsonized pathogens and is important in mediating their phagocytosis [17]. CR3 is expressed on immature and mature macrophages, neutrophils, DCs and MCs [42,59].

Deficiencies in complement or CRs are known to increase susceptibility to certain infections such as group B Streptococcus and lymphocytic choriomeningitis virus (LCMV), highlighting the important role for the complement system in activating protective immunity [65,66]. Complement deficiencies are also associated with the loss of tolerance to self proteins and the development of IC-mediated ADs such as systemic lupus erythematosus (lupus) and myocarditis [60,6770]. CD11b/CR3 expressed on macrophages was found to generate an inhibitory signal to T cells [7,68]. In a low-dose oral tolerance model, CD11b deficient mice developed significantly increased inflammation, IL-6 and a Th17 response indicating that CD11b reduces inflammation [68,70]. In a separate study, binding of iC3b to CD11b/CR3 was shown to be necessary for the development of oral and peripheral tolerance during delayed-type hypersensitivity (DTH) responses by increasing expression of IL-10 and TGF-β [62,70]. iC3b had to be present during the first 12 hours of antigen presentation to mediate this tolerogenic affect [62]. Although the role of MDSCs or M2 were not specifically examined in these studies, the ability of CD11b+ cells to inhibit inflammation and T cell responses and to produce TGF-β and IL-10 suggests that they could be alternatively activated or suppressive macrophages.

We have shown that CR1/2 deficiency significantly increases acute myocarditis, IC-deposition, fibrosis and dilated cardiomyopathy (DCM) at day 10 post infection (pi) following CVB3/cardiac myosin inoculation [60]. Usually DCM does not develop until around day 35 pi in this model [45], indicating that deficiency in CR1/2 signaling accelerates fibrosis and the development of chronic heart disease. CD11b+GR1+(Ly6G)F4/80+ macrophages expressing the MR, TLR4, Tim-3, IL-4R, caspase-1, IL-1β and IL-10 were significantly increased in the hearts of CR1/2 deficient mice, indicating that CRs usually inhibit this potentially profibrotic population (Fig. 1). Recently, caspase-1, which cleaves proIL-1β to its active form, was shown to regulate the activity of other proteins important for fibrosis including fibroblast growth factor (FGF)-2 and MMP14 [71]. We also observed a significant increase in CD11b+GR1+F4/80+ macrophages at 12 hours pi in the spleen of CR1/2 deficient mice, suggesting that these cells influence the adaptive immune response (D. Fairweather, unpublished data). Recall that a similar observation was made for innate CD11b+GR1+F4/80+ macrophages following S. mansoni infection and for tolerance following DTH [8,62]. Thus, CR1/2 signaling not only activates immunity by interacting with pathogen-antibody ICs, but also regulates profibrotic TLR4+IL-1β+ M2.

Figure 1
Complement receptor 1/2 (CR1/2) deficiency increases fibrosis and alternatively activated macrophages in the heart during acute coxsackievirus B3 (CVB3) myocarditis. Male A/J mice deficient in CR1/2 (red lettering) upregulate the mannose receptor (CD206), ...

3. M2 and autoimmune diseases

Although the hallmark of AD is the generation of autoantigen-specific T and B cell responses, macrophages and neutrophils comprise the majority of the infiltrate during the peak of acute inflammation [42,72]. Other factors critical in determining the development of AD include genetic background and sex [31,42,45,53,73]. For example, BALB/c mice develop predominant Th2 and M2 responses following infection or adjuvant inoculation compared to C57BL/6 mice due to their high numbers of MCs, which are an important innate source of IL-4 for differentiation of monocytes and naïve T cells to M2 and Th2 cells [2,3,42,73]. Furthermore, estrogen in female BALB/c mice increases Th2 responses by upregulating GATA3 and inhibiting NFκB [53,74,75].

3.1 Sex hormones and cell-mediated vs. antibody-mediated ADs

ADs affect approximately 5–8% of the population, making them the third most common disease in the US after cardiovascular disease and cancer. Conservative estimates indicate that almost 80% of the people with ADs are women [7678]. Although studies of estrogen’s effects on immune function have been contradictory, many reports indicate that estrogen not only stimulates antibody production from B cells but also increases IL-4, IL-10 and TGF-β thereby increasing fibrosis while downregulating Th1-type proinflammatory responses [53,7981]. Although the role of estrogen in macrophage differentiation has not yet been examined, known effects of estrogen on the immune system would be expected to increase M2 and MDSC populations. Recall that M2 and MDSCs express Arg1 and are associated with increased Treg and Th2 responses [3,12,19]. We have found that female BALB/c mice express significantly elevated levels of IL-4 (Th2), a greater percentage of B cells and CD25+Foxp3+ Treg, and increased expression of Tim-3 on MCs, macrophages and T cells in the heart compared to males with acute CVB3-induced myocarditis [42]. Tim-3 is located in the same region of chromosome 11 (human 5q23-35) as the IL-4 gene cluster that includes IL-4, IL-5, IL-13 and GM-CSF and several other immune-related genes such as IL-12 p40, CD14 (part of the TLR4 complex) and Itk [49]. In mice, chromosome 11 has been linked with susceptibility to type 1 diabetes (Idd4) and EAE (Eae6) [49]. Comparing males to females, we find that females upregulate the M2 marker Arg1 in the heart during acute CVB3-induced myocarditis as assessed by microarray analysis, as well as other markers of M2 differentiation including Dectin-1, CD169, Galectin-3, CCL2, CCL7, and CXCL3 (D. Fairweather, unpublished data).

In ADs that are more prevalent in males, such as myocarditis, acute inflammation is characterized by increased numbers of macrophages and neutrophils and a more Th1/Th17-type immune response [42, 53]. In genetically susceptible mouse strains (i.e. BALB/c and A/J) the acute phase progresses to a chronic phase with increased autoantibodies and fibrosis indicating a switch from a Th1 to a Th2-type response [45,53]. In contrast, a dominant Th2 response initiates disease in females and predisposes them to increased acute and chronic antibody/IC-mediated tissue damage and fibrosis, characteristics that are more prevalent in women with ADs such as lupus and arthritis. Thus, in general testosterone appears to increase cell-mediated pathology in males while estrogen increases antibody-mediated, fibrotic pathology in females. However, it is important to realize that both male and female mice mount a “mixed” Th1/Th2/Th17 response to infection or adjuvant [50,53,82]. In a similar manner we would anticipate a mix of M1 and M2 macrophages in the infiltrate during AD (Fig. 2) [50,82]. During acute experimental autoimmune myocarditis (EAM) nearly 70% of the myocardial infiltrate are alternatively activated based on expression of SR-A (CD204), around 10% of the CD11b+ infiltrate express both the MR (CD206) and SR-A (CD204) (data not shown), while about 15% are CD11b+ (CD204neg and CD206neg) M1 (Fig. 2A) [82]. In contrast, during acute CVB3 myocarditis approximately 70% of the F4/80+ macrophages in the heart are GR1negCD11b+ M1 compared to around 30% GR1+CD11b+ M2/MDSC (Fig. 2B) [50]. Following gonadectomy of male BALB/c mice, M2 levels increase from around 30% to nearly 50% resulting in decreased acute CVB3 myocarditis [50]. These findings indicate that fluctuating levels of M1 to M2 influence autoimmune heart disease.

Figure 2
Alternatively activated macrophages in autoimmune myocarditis. A) Experimental autoimmune myocarditis (EAM) was induced using the myocarditogenic peptide MyHCα614–629 derived from the murine cardiac myosin heavy chain emulsified in complete ...

Regardless of sex, BALB/c and A/J mice develop dominant Th2 responses with more MCs and M2 than C57BL/6 mice [3,73]. Signaling via IL-4Rα has been shown to induce arginase and a M2 phenotype in BALB/c mice [83]. We were initially surprised to find that it was GR1+F4/80+ M2/MDSC rather than GR1negF4/80+ M1 that expressed TLR4, Tim-3 and IL-1β in the heart of males with acute CVB3-induced myocarditis (Fig. 2C) [50]. This population also expresses the IL-4R and IL-10 (Fig. 2C) and could be similar to the M2b described by Martinez et al. [2]. Our findings suggest that TLR4+caspase-1+IL-1β+ M2 could contribute to the pathogenesis of AD by increasing fibrosis (Fig. 1). Thus, an elevated Th1-type M1 compared to M2 response to CVB3/cardiac myosin in BALB/c males increases cell-mediated inflammation but enables clearance of the virus (Fig. 2) [42,50]. However, elevated TLR4+caspase-1+IL-1β+ M2 in males promote chronic fibrosis and DCM (Fig. 1) [60]. Women are known to develop strong Th2 responses and elevated antibodies in response to infections [53]. If women develop increased numbers of TLR4+FcγR+IL-1β+ M2 (M2b) following infection resulting in more IC deposition and fibrosis- the hallmark of AD pathology in females- this could explain, at least in part, why women are at an increased risk of developing ADs [2,53]. There is some evidence to support the idea that estrogen increases IL-1β and M2 responses. Estrogen was shown to increase expression of MCP-1/CCL2, which is a marker of M2 [3,84]. In a separate study, MCP-1 was found to be important for inflammatory recruitment in EAM increasing IL-4 and IL-1β levels in the heart [85]. However, the role of M2 cells was not specifically examined in the study.

3.2 Evidence for M2 in ADs

There are few studies specifically examining the role of M2 or MDSCs in the development of ADs. Most experimental models of AD, such as EAE, collagen-induced arthritis (CIA) and EAM, use CFA supplemented with M. tuberculosis to induce disease and are considered to be Th1 and/or Th17-mediated [53]. However, IL-4 and IL-13-induced Th2 responses are necessary for the development of several ADs usually considered to be mediated by Th1 or Th17 responses such as EAE, EAM and CVB3-induced myocarditis [82,8690]. Many PRRs that are present on M2 and MDSCs, such as MR, Dectin-1, CD163, DC-SIGN and MGL-1/2, are able to recognize both foreign and self antigens suggesting a possible role for alternatively activated suppressor macrophages in the pathogenesis of AD [1].

3.3 ADs more prevalent in Females

Multiple sclerosis

Multiple sclerosis affects women about 2 times more frequently than men [53]. EAE, an animal model of multiple sclerosis, is induced in many species including mice by inoculation of an equal volume of self-tissue such as whole myelin homogenates, MBP, MOG or PLP with CFA containing M. tuberculosis boosted with Bordetella pertussis [91,92]. The acute phase of EAE has been associated with a Th1 and/or Th17 response and the chronic phase with a Th2 response, TGF-β and IL-10. Immunization with MOG in particular induces both cellular and antibody-mediated pathology and chronic EAE in female C57BL/6 mice [91]. Although Th2 responses have been shown to protect against acute inflammation in EAE in mice, they have been found to severely aggravate disease in primates [91]. IFN-γ deficient mice develop more severe EAE, which is thought to be due to increased IL-17 levels (IL-17 deficient mice have reduced EAE indicating that IL-17 increases disease) [92]. However, IL-4 levels are also increased in IFN-γ deficient mice and are believed to be responsible for increasing disease in CVB3 myocarditis and EAM models [86,88,90].

CD11b+ macrophages are major effector cells in EAE associated with Th1 responses in C57BL/6 females [91,93]. EAE in BALB/c mice induces splenic CD11b+ suppressor cells that express GR1 at day 10 to 14 post inoculation [94]. The most potent population of CD11b+GR1+F4/80+ suppressor cells in the spleen were identified as immature Ly-6ChiCD11b+ cells that inhibited CD4+ and CD8+ T cells via IFN-γ-mediated NO production. The cells did not express Arg1, but could produce arginase when treated with IL-4 in culture. During peak, acute EAE at day 14 MSDCs comprised approximately 30% of the inflammatory cells in the CNS, reminiscent of the 30% CD11b+GR1+F4/80+ population observed in the heart during CVB3 myocarditis (Fig. 2B).

The most convincing evidence for a role for M2 in EAE comes from a study by Ponomarev and colleagues showing that CD11b+ microglial cells isolated from the CNS during disease expressed IL-4 and Ym1 but not NO, indicating that they were M2 [89]. IL-4 was shown to increase Ym1 expression in microglial cell cultures, and IL-4 or IL-4R deficient microglial cells did not produce Ym1. The investigators concluded that M2 can be pathogenic and not just protective.

Arthritis

The incidence of rheumatoid arthritis is higher in women than men (3:1) [53]. In experimental models of arthritis including CIA, the K/BxN mouse rheumatoid arthritis model and Lyme disease arthritis induced by infection with the spirochete Borrelia burgdorferi, recruitment of GR1+/hi neutrophils to the joint was found to be necessary for disease development in BALB/c compared to C57BL/6 mice [95]. Additionally, gene expression profiles of peripheral blood cells from patients with new-onset systemic juvenile idiopathic arthritis revealed that patients with disease had increased markers for M2 and genes involved in the TLR/IL-1R signaling pathways [96]. Although sex hormones do not appear to be a factor in disease pathogenesis in juvenile patients, this study suggests a pathologic role for upregulation of TLR/IL-1R and M2 macrophages.

Lupus

SLE occurs in women compared to men at a ratio of 9:1 [53]. In a tetramethylpentadecane (TMPD) model of lupus, mice develop autoantibodies against dsDNA and small nuclear RNPs resulting in IC-mediated glomerulonephritis and arthritis [97]. Increased IFN-stimulated genes correlate with active disease and precede the development of disease in mice. TMPD was found to increase a population of CD11b+Ly6Chi immature monocytes that express type I IFNs and whose numbers directly correlate with the production of lupus autoantibodies. This study points to an increase in innate proinflammatory markers and suppressive macrophages associated with IC-mediated pathology.

3.4 ADs more prevalent in Males

Myocarditis

The incidence and severity of heart disease, including myocarditis and DCM, is higher in men [98]. The severity of inflammation is also increased in males in murine models of CVB3-induced myocarditis and EAM [42,82,99,100]. CD11b+ monocytes are the major infiltrate during EAM at day 21 post inoculation and CVB3 myocarditis at day 10 post infection in BALB/c mice [42,72]. In EAM approximately 70% of the CD11b+F4/80+ macrophage infiltrate is alternatively activated based on expression of SR-A (CD204), while only around 30% of the CD11b+GR1+F4/80+ macrophages are M2 based on MR (CD206) expression during CVB3 myocarditis (Fig. 2A,B) [50,82]. IL-13 deficiency in EAM significantly decreases the percentage of CD204+CD206+F4/80+M2 in the heart indicating that IL-13 is partially responsible for driving M2 differentiation in acute myocarditis [82]. In a separate study, IL-17 was shown to increase recruitment of CD11b+GR1+F4/80+ macrophages to the heart during EAM, which were able to suppress Th17 cells by an IFN-γ-dependent NO mechanism [101]. The investigators considered the cells to be mature macrophages due to low level MHC class II expression. The suppressor cells upregulated NOS2 when stimulated in culture with IFN-γ and LPS. Although the requirement for IFN-γ could indicate M1, the expression of CD11b and GR1 on these cells suggests the possibility that they are MDSCs (Table 1). Thus, IL-17 may promote autoimmune heart disease by increasing M2/MDSC populations. We also observe an increased Th17 response in CR1/2 deficient mice during acute CVB3-induced myocarditis (unpublished data) as well as increased CD11b+GR1+F4/80+ M2/MDSCs (Fig. 1). We have shown that M2/MDSCs are the primary macrophages expressing TLR4 and Tim-3 and that cross-talk by these receptors regulates the severity of CVB3 myocarditis in BALB/c males (Fig. 2C) [41,42,48,50]. Furthermore, regulation by CR1/2 signaling decreases the percentage of TLR4+caspase-1+IL-1β+ M2/MDSCs in the heart during acute CVB3 myocarditis thereby reducing chronic fibrosis and DCM (Fig. 1). Thus, maintaining an appropriate ratio of M1 to M2 in the heart following infection is critical for elimination of pathogens and regulation of inflammation and wound healing without the negative consequences of fibrotic pathology.

4. Concluding Remarks

Alternatively activated macrophages are induced by the Th2-type cytokines IL-4 and IL-13 and are well known for their ability to inhibit proinflammatory responses by the release of IL-10 and TGF-β. M2 and MDSCs are also induced in response to viral and bacterial infections usually associated with Th1 or Th17-type responses, such as CVB3, M. tuberculosis and CFA supplemented with M. tuberculosis and pertussis toxin that is used to induce AD in animal models (Table 1). Recent findings in animal models suggest that M2 and/or MDSCs exacerbate autoimmune disease by presenting self antigens taken up by scavenger receptors in response to tissue damage and by contributing to fibrosis and IC-mediated pathology. We were surprised to discover that the “proinflammatory” TLR4+caspase-1+IL-β+ macrophages that are increased in the heart during acute CVB3-induced myocarditis and EAM were M2 rather than M1 cells (Fig. 2) [50,82]. CR1 is critical for clearing ICs, and CR1/2 deficient mice have increased IC deposition, fibrosis and TLR4+ caspase-1+IL-1β+ M2 in the heart during acute CVB3-induced myocarditis (Fig. 1) [60]. Evidence is beginning to emerge that M2 may also be pathogenic in EAE, arthritis and lupus. However, few studies of AD have specifically examined the role of M2 or MDSCs in the pathogenesis of disease. Realizing that proinflammatory receptors such as TLR4 and the IL-1R drive M2 differentiation indicates that an evaluation of the role of M1 vs. M2 macrophages in the pathogenesis of autoimmune disease is needed. As noted by several other contributors to this special issue, we are pleased to include this paper in the issue devoted to the recognition of Noel Rose. We note that this is part of the series of the Journal of Autoimmunity dedicated to major fields in autoimmunology [110113]. Noel Rose has contributed enormously to many fields in autoimmunity and including his major efforts in developing the American Autoimmune Related Diseases Association (AARDA) [114119].

Acknowledgments

Work discussed in this review was supported by NIH R01 grants HL087033 (D.F.) and HL67290, HL70729 and a Fellowship Grant from the Myocarditis Foundation (D.C.).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Van Ginderachter JA, Movahedi K, Ghassabeh GH, Meerschaut S, Beschin A, Raes G, de Baetselier P. Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiol. 2006;211:487–501. [PubMed]
2. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–461. [PubMed]
3. Martinez FO, Helming LM, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–483. [PubMed]
4. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–4506. [PMC free article] [PubMed]
5. Gordon S. The macrophage: past, present and future. Eur J Immunol. 2007;37:S9–S17. [PubMed]
6. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037–3047. [PMC free article] [PubMed]
7. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol. 2008;181:5829–5835. [PubMed]
8. Atochina O, Daly-Engel T, Piskorska D, McGuire E, Harn DA. A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr-1+ macrophages that suppress naïve CD4+ T cell proliferation via an IFN-γ and nitric oxide-dependent mechanism. J Immunol. 2001;167:4293–4302. [PubMed]
9. Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev. 2000;177:141–149. [PubMed]
10. Bogdan C, Paik J, Vodovotz Y, Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem. 1992;267:23301–23308. [PubMed]
11. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155–1166. [PMC free article] [PubMed]
12. Anthony RM, Rutitzky LI, Urban JF, Jr, Stadecker MJ, Gause WC. Protective immune mechanisms in helminth infection. Nat Rev Immunol. 2007;7:975–987. [PMC free article] [PubMed]
13. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo M, Basaraba RJ, Konig T, Schleicher U, Koo M-S, Kaplan G, Fitzgerald KA, Tuomanen EI, Orme IM, Kanneganti T-D, Bogdan C, Wynn TA, Murray PJ. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol. 2008;9:1399–1406. [PMC free article] [PubMed]
14. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287–292. [PMC free article] [PubMed]
15. Chieppa M, Bianchi G, Doni A, Prete AD, Sironi M, Laskarin G, Monti P, Piemonti L, Biondi A, Mantovani A, Introna M, Allavena P. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol. 2003;171:4552–4560. [PubMed]
16. Nickel T, Schmauss D, Hanssen H, Sicic Z, Krebs B, Jankl S, Summo C, Fraunberger P, Walli AK, Pfeiler S, Weis M. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis. 2009 Jan 9; Epub ahead of print. [PubMed]
17. Kerrigan AM, Brown GD. C-type lectins and phagocytosis. Immunobiol. 2009;214:562–575. [PMC free article] [PubMed]
18. Goni O, Alcaide P, Fresno M. Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1+)CD11b+ immature myeloid suppressor cells. Int Immunol. 2002;14:1125–1134. [PubMed]
19. De Santo C, Salio M, Masri SH, Lee LY-H, Dong T, Speak AO, Porubsky S, Booth S, Veerapen N, Besra GS, Grone H-J, Platt FM, Zambon M, Cerundolo V. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest. 2008;118:4036–4048. [PubMed]
20. Mordue DG, Sibley LD. A novel population of Gr-1+-activated macrophages induced during acute toxoplasmosis. J Leukoc Biol. 2003;74:1015–1025. [PubMed]
21. Li Q, Pan P-Y, Gu P, Xu D, Chen S-H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 2004;64:1130–1139. [PubMed]
22. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166:5398–5406. [PubMed]
23. Mencacci A, Montagnili C, Bacci A, Cenci E, Pitzurra L, Spreca A, Kopf M, Sharpe AH, Romani L. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol. 2002;169:3180–3190. [PubMed]
24. Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony- stimulating factor and neutrophils- forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006;2:500–510. [PubMed]
25. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880–4891. [PubMed]
26. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment. Nat Rev Immunol. 2007;7:41–51. [PubMed]
27. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, van Rooijen N, Takenaka H, D’Amore PA, Stein-Streilein J, Losordo DW, Streilein JW. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115:2363–2372. [PMC free article] [PubMed]
28. Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamognone L, Giordano S. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med. 2008;205:1673–1685. [PMC free article] [PubMed]
29. Fairweather D, Frisancho-Kiss S, Rose NR. Viruses as adjuvants for autoimmunity: evidence from coxsackievirus-induced myocarditis. Rev Med Virol. 2005;15:17–27. [PubMed]
30. Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol. 2007;17:35–43. [PubMed]
31. Fairweather D, Rose NR. Immunopathogenesis of autoimmune disease. In: Luebke R, House R, Kimber I, editors. Immunotoxicology and Immunopharmacology. 3. CRC Press; Boca Raton FL: 2007. pp. 423–436.
32. Papadimitraki ED, Bertsias GK, Boumpas DT. Toll like receptors and autoimmunity: a critical appraisal. J Autoimm. 2007;29:310–318. [PubMed]
33. Lang KS, Burow A, Kurrer M, Lang PA, Recher M. The role of the innate immune response in autoimmune disease. J Autoimm. 2007;29:206–212. [PubMed]
34. Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune response: triggers of or triggered by autoimmunity? Nat. Rev Immunol. 2009;9:246–258. [PMC free article] [PubMed]
35. Varani S, Frascaroli G, Landini MP, Soderberg-Naucler C. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol. 2009;19:131–145. [PubMed]
36. Banus S, Stenger RM, Gremmer ER, Dormans JA, Mooi FR, Kimman TG, Vandebriel RJ. The role of Toll-like receptor-4 in pertussis vaccine-inuduced immunity. BMC Immunol. 2008;9:21. [PMC free article] [PubMed]
37. Rocha-Ramirez LM, Estrada-Garcia I, Lopez-Marin LM, Sequra-Salinas E, Mendez-Aragon P, Van Soolingen D, Torres-Gonzalez R, Chacon-Salinas R, Estrada-Parra S, Maldonado-Bernal C, Lopez-Macias C, Isibasi A. Mycobacterium tuberculosis lipids regulate cytokines, TLR-2/4 and MHC class II expression in human macrophages. Tuberculosis (Edinb) 2009;88:212–220. [PubMed]
38. Drage MG, Pecora ND, Hise AG, Febbraio M, Silverstein RL, Golenbock DT, Boom WH, Harding CV. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol. 2009;258:29–37. [PMC free article] [PubMed]
39. Kleinnijenhuis J, Joosten LA, van de Veerdonk FL, Savage N, van Crevel R, Kullberg BJ, van der Ven A, Ottenhoff TH, Dinarello CA, van der Meer JW, Netea MG. Transcriptional and inflammasome-mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis. Eur J Immunol. 2009 Jun 19; Epub ahead of print. [PubMed]
40. Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol. 2009 Jun 5; Epub ahead of print. [PMC free article] [PubMed]
41. Fairweather D, Yusung S, Frisancho(-Kiss) S, Barrett M, Gatewood S, Steele R, Rose NR. IL-12Rβ1 and TLR4 increase IL-1β and IL-18-associated myocarditis and coxsackievirus replication. J Immunol. 2003;170:4731–4737. [PubMed]
42. Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Rose NR, Fairweather D. Cutting Edge: Cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178:6710–6714. [PubMed]
43. O’Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009;61:177–197. [PubMed]
44. Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis. Methods Mol Biol. 2009;517:329–343. [PubMed]
45. Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods. 2007;41:118–122. [PMC free article] [PubMed]
46. Dai J, Liu B, Li Z. Regulatory T cells and Toll-like receptors: what is the missing link? Int. Immunopharmacol. 2009;9:528–533. [PMC free article] [PubMed]
47. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VJ. Th1-specific cell surface protein Tim-3 regulates macrophage activation and the severity of autoimmune disease. Nature. 2002;415:536–541. [PubMed]
48. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJL, Njoku DB, Cihakova D, Silbergeld EK, Rose NR, Fairweather D. Cutting Edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol. 2006;176:6411–6415. [PubMed]
49. Kuchroo VK, Meyers JH, Umetsu DT, DeKruyff RH. TIM family genes in immunity and tolerance. Adv Immunol. 2006;91:227–249. [PubMed]
50. Frisancho-Kiss S, Coronado MJ, Frisancho JA, Lau VM, Rose NR, Klein SL, Fairweather D. Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun. 2009;23:649–657. [PMC free article] [PubMed]
51. Terrazas LI, Walsh KL, McGuire E, Harn DA., Jr The schistosome oligosaccharide lacto-N-neotetraose expands Gr-1+ cells that secrete anti-inflammatory cytokines and inhibit proliferation of naïve CD4+ T cells: a potential mechanism for immune polarization in helminth infections. J Immunol. 2001;167:5294–5303. [PubMed]
52. Sewell DL, Reinke EK, Hogan LH, Sandor M, Fabry Z. Immunoregulation of CNS autoimmunity by helminth and mycobacterial infections. Immunol Letters. 2002;82:101–110. [PubMed]
53. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathologic perspective. Am J Pathol. 2008;173:600–609. [PubMed]
54. Smith P, Mangan NE, Walsh CM, Fallon RE, McKenzie ANJ, van Rooijen N, Fallon PG. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol. 2007;178:4557–4566. [PubMed]
55. Morgan BP, Harris CL. The complement system: a brief overview. In: Morgan BP, Harris CL, editors. Complement Regulatory Proteins. Academic Press; San Diego: 1999. pp. 1–31.
56. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human disease: lessons from complement deficiencies. Mol Immunol. 2009 Epub ahead of print. [PubMed]
57. Roosendaal R, Carroll MC. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev. 2007;219:157–166. [PubMed]
58. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271:348–350. [PubMed]
59. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol. 2004;41:1089–1098. [PubMed]
60. Fairweather D, Frisancho-Kiss S, Njoku DB, Nyland JF, Kaya Z, Yusung SA, Davis SE, Frisancho JA, Barrett MA, Rose NR. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis and heart failure by increasing macrophages, IL-1β and immune complex deposition in the heart. J Immunol. 2006;176:3516–3524. [PubMed]
61. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol. 2001;2:739–745. [PubMed]
62. Sohn J-H, Bora PS, Suk H-J, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med. 2003;9:206–212. [PMC free article] [PubMed]
63. Kurtz CB, O’Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol. 1990;144:3581–3591. [PubMed]
64. Morgan BP, Harris CL. Complement regulatory proteins in other species. In: Morgan BP, Harris CL, editors. Complement Regulatory Proteins. Academic Press; San Diego: 1999. pp. 226–242.
65. Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of pathogens- acquisition of inhibitors and beyond. Mol Immunol. 2009 Epub ahead of print. [PubMed]
66. Suresh M, Molina H, Salvato MS, Mastellos D, Lambris JD, Sandor M. Complement component 3 is required for optimal expansion of CD8 T cells during systemic viral infection. J Immunol. 2003;170:788–794. [PubMed]
67. Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 1986;29:739–747. [PubMed]
68. Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med. 2007;204:1519–1524. [PMC free article] [PubMed]
69. Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2; CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol. 1997;159:1557–1569. [PubMed]
70. Veldhoen M. Oral tolerance: passing CD11b on the way to tolerance. Immunol Cell Biol. 2007;85:397–398. [PubMed]
71. Keller M, Ruegg A, Werner S, Beer H-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 2008;132:818–831. [PubMed]
72. Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 2008;99:95–114. [PubMed]
73. Fairweather D, Frisancho-Kiss S, Gatewood S, Njoku D, Steele R, Barrett M, Rose NR. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity. 2004;37:131–145. [PubMed]
74. Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC. Reciprocal antagonism between estrogen receptor and NF-κB activity in vivo. Circ Res. 2001;89:823–830. [PubMed]
75. Lacroix M, Leclercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-a gene (ESR1) in breast cancer. Mol Cell Endocrin. 2004;219:1–7. [PubMed]
76. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune disease in the United States. Clin Immunol Immunopathol. 1997;84:223–243. [PubMed]
77. Dooley MA, Hogan SL. Environmental epidemiology and risk factors for autoimmune disease. Curr Opin Rheumatol. 2003;15:99–103. [PubMed]
78. Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28:1–6. [PubMed]
79. Salem ML. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammation by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy. 2004;3:97–104. [PubMed]
80. Dimayuga FO, Reed JL, Carnero GA, Wang C, Dimayuga ER, Dimayuga VM, Perger A, Wilson ME, Keller JN, Bruce-Keller AJ. Estrogen and brain inflammation: effects on microglial expression of MHC, costimulatory molecules and cytokines. J Neuroimmunol. 2005;161:123–136. [PubMed]
81. Straub RH. The complex role of estrogens in inflammation. Endocrine Rev. 2007;28:521–574. [PubMed]
82. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, Talor MV, Baldeviano GC, Frisancho-Kiss S, Gabrielson K, Bedja D, Rose NR. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol. 2008;172:1195–1208. [PubMed]
83. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636–645. [PubMed]
84. Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA. 17β-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood. 2004;104:1404–1410. [PubMed]
85. Goser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, Egashira K, Rose NR, Katus HA, Kaya Z. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1a in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation. 2005;112:3400–3407. [PubMed]
86. Afanasyeva M, Wang Y, Kaya Z, Park S, Zilliox MJ, Schofield BH, Hill SL, Rose NR. Experimental myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol. 2001;159:193–203. [PubMed]
87. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Molec Med. 2001;7:115–121. [PubMed]
88. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Gatewood SJL, Davis SE, Njoku DB, Rose NR. IFN-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-β1, IL-1β, and IL-4 in the heart. Am J Pathol. 2004;165:1883–1894. [PubMed]
89. Ponomarev ED, Maresz K, Tan Y, Dittel BN. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci. 2007;27:10714–10721. [PubMed]
90. Afanasyeva M, Georgakopoulos D, Fairweather D, Caturegli P, Kass DA, Rose NR. A novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-γ knockout mice. Circulation. 2004;110:2910–2917. [PubMed]
91. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. In: Scolding NJ, Gordon D, editors. Methods in Molecular Biology, Neural Cell Transplantation. Vol. 549. Humana Press; 2009. pp. 159–173.
92. Hofstetter HH, Gold R, Hartung H-P. Th17 cells in MS and experimental autoimmune encephalomyelitis. Intern MS J. 2009;16:12–18. [PubMed]
93. Sinha S, Kaler LJ, Proctor TM, Teuscher C, Vandenbark AA, Offner H. IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol. 2008;180:2679–2685. [PMC free article] [PubMed]
94. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK, Khoury SJ. CD11b+Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol. 2007;179:5228–5237. [PubMed]
95. Brown CR, Blaho VA, Loiacono CM. Treatment of mice with the neutrophil-depleting antibody RB6-8C5 results in early development of experimental Lyme arthritis via the recruitment of Gr-1 polymorphonuclear leukocyte-like cells. Infect Immun. 2004;72:4956–4965. [PMC free article] [PubMed]
96. Fall N, Barnes M, Thronton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56:3793–3804. [PubMed]
97. Lee PY, Wienstein JS, Nacionales DC, Scumpia PO, Li Y, Butfiloski E, van Rooijen N, Moldawer L, Satoh M, Reeves WH. A novel type I IFN-producing cell subset in murine lupus. J Immunol. 2008;180:5101–5108. [PMC free article] [PubMed]
98. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocrine Rev. 2003;24:313–340. [PubMed]
99. Huber SA, Job LP, Woodruff JF. Sex-related differences in the pattern of coxsackievirus B-3-induced immune spleen cell cytotoxicity against virus-infected myofibers. Infect Immun. 1981;32:68–73. [PMC free article] [PubMed]
100. Huber SA. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med Microbiol Immunol. 2005;194:121–127. [PubMed]
101. Valaperti A, Marty RR, Kania G, Germano D, Mauermann N, Dirnhofer S, Leimenstoll B, Blyszczuk P, Dong C, Mueller C, Hunziker L, Eriksson U. CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis. J Immunol. 2008;180:2686–2695. [PubMed]
102. Pecora ND, Fulton SA, Reba SM, Drage MG, Simmons DP, Urankar-Nagy NJ, Boom WH, Harding CV. Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cell Immunol. 2009;254:94–104. [PMC free article] [PubMed]
103. Turcotte K, Gauthier S, Mitsos LM, Shustik C, Copeland NG, Jenkins NA, Fournet JC, Jolicoeur P, Gros P. Genetic control of myeloproliferation in BXH-2 mice. Blood. 2004;103:2343–2350. [PubMed]
104. Kaparakis M, Walduck AK, Price JD, Pedersen JS, van Rooijen N, Pearse MJ, Wijburg OL, Strugnell RA. Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL/6 mice. Infect Immun. 2008;76:2235–2239. [PMC free article] [PubMed]
105. Dumrese C, Slomianka L, Ziegler U, Choi SS, Kalia A, Fulurija A, Lu W, Berg DE, Benghezal M, Marshall B, Mittl PR. The secreted Helicobacter cysteine-rich protein A causes adherence of human monocytes and differentiation into a macrophage-like phenotype. FEBS Lett. 2009;583:1637–1643. [PMC free article] [PubMed]
106. Pauksens K, Fjaertoft G, Douhan-Hakansson L, Venge P. Neutrophil and monocyte receptor expression in uncomplicated and complicated influenza A infection with pneumonia. Scand J Infect Dis. 2008;40:326–337. [PubMed]
107. Van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, Joosten I, van den Berg WB, Williams DL, van der Meer JW, Joosten LA, Netea MG. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe. 2009;5:311–313. [PubMed]
108. Heinsbroek SE, Taylor PR, Martinez FO, Martinez-Pomares L, Brown GD, Gordon S. Stage-specific sampling by pattern recognition receptors during Candida albicans phagocytosis. PLoS Pathog. 2008;4:e1000218. [PMC free article] [PubMed]
109. Cuervo H, Pineda MA, Aoki MP, Gea S, Fresno M, Girones N. Inducible nitric oxide synthase and arginase expression in heart tissue during acute Trypanosoma cruzi infection in mice: arginase I is expression in infiltrating CD68+ macrophages. J Infect Dis. 2008;197:1772–1782. [PubMed]
110. Whittingham S, Rowley MJ, Gershwin ME. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun. 2008;31:197–200. [PubMed]
111. Gershwin ME. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun. 2008;30:105–107. [PubMed]
112. Blank M, Gershwin ME. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun. 2008;30:1–4. [PubMed]
113. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmmun. 2008;31:325–330. [PubMed]
114. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun. 2008;30:5–11. [PMC free article] [PubMed]
115. Burek CL, Rose NR. Autoimmune thyroiditis and ROS. Autoimmun Rev. 2008;7:530–537. [PubMed]
116. Cooper GS, Gilbert KM, Greidinger EL, James JA, Pfau JC, Reinlib L, Richardson BC, Rose NR. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Environ Health Perspect. 2008;116:695–702. [PMC free article] [PubMed]
117. Li HS, Ligons DL, Rose NR. Genetic complexity of autoimmune myocarditis. Autoimmun Rev. 2008;7:168–173. [PMC free article] [PubMed]
118. Njoku DB, Li Z, Mellerson JL, Sharma R, Talor MV, Barat N, Rose NR. IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis. J Autoimmun. 2009;32:52–59. [PMC free article] [PubMed]
119. Rose NR, Talor E. Antigen-specific immunoregulation and autoimmune thyroiditis. Ann N Y Acad Sci. 1991;636:306–320. [PubMed]